Drive Impactful Science from Bench to Market
Learn how Certara drives impactful science.
Jim Gallagher2021 年 6 月 14 日
Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021 年 6 月 11 日
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021 年 6 月 11 日
Certara Acquires UK-based Insight Medical Writing
Expands global reach and deepens regulatory expertise PRINCETON, NJ.— 2021 年 6 月 10 日– Certara, Inc., the…
Jieun Choe2021 年 6 月 10 日
Your First Choice in Complex Biologics Drug Development
The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…
Certara2021 年 6 月 1 日
De-risk your program with evidence-based secondary pharmacology insights
Safety issues account for about a quarter of the attrition in drug projects and can…
Jim Gallagher2021 年 5 月 28 日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 26 日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 26 日
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 25 日
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
Jim Gallagher2021 年 5 月 25 日
